Skip to content
Find an ETF
← All ETFs

iShares Nasdaq US Biotechnology UCITS ETF

iShares · tracks Nasdaq US Biotechnology ?
StocksReinvestsOwns the sharesIE
Mid-range feeReinvests dividendsOwns the shares directlyUnited StatesConcentrated in a few names
TER ?
0.35%
Distribution ?
Accumulating
Replication ?
Physical Full
Fund size ?
€973.4M
Domicile ?
IE
Fund currency ?
USD
Launched
2017 (9-year track record)
Holdings
261 positions
Regulation
UCITS

What this fund is

iShares Nasdaq US Biotechnology UCITS ETF is an exchange-traded fund (ETF) from iShares, traded under the ticker BTEK (ISIN IE00BYXG2H39). It lets you buy a basket of holdings in a single trade, spreading your money across them rather than one company. At its core it is a focused, thematic fund: it concentrates on the health care part of the market, so it lives or dies by that one area rather than the economy as a whole. Underneath, it is about owning small slices of companies, so you share in their growth when they do well — and their falls when they don't. It passively tracks the Nasdaq US Biotechnology index — mirroring that market instead of paying a manager to pick winners, which keeps costs low, and its largest holdings include VERTEX PHARMACEUTICALS INC, AMGEN INC and GILEAD SCIENCES INC.

Spread across roughly 261 holdings (the ten largest ≈ 41.3%), no one position makes or breaks the fund. Its biggest country exposures are ~93.1% United States, ~1.8% Belgium and ~1.3% Denmark. Its heaviest sectors are ~100% Health Care and ~0.1% Other. A focused fund like this is typically held as a smaller 'satellite' position around a broader core — a way to lean into one theme, not usually a portfolio's only holding. Its ongoing charge (TER) is 0.35% a year — about €35 a year on a €10,000 holding, taken automatically from the fund.

Income such as dividends is automatically reinvested inside the fund (an accumulating share class), so returns compound without you doing anything. It holds the underlying investments directly (physical replication); it is domiciled in Ireland and UCITS-regulated, a European standard built to protect everyday investors and trades in USD. Its price has swung about 17.7% over the past year, which describes how much its price tends to move rather than whether it is good. It launched in 2017. As with any investment, its value can go down as well as up, and past performance is not a guide to future results. (Fund data sourced from iShares.)

Performance

+54.3%
1-year return · USD · as of 2026-07-02
Total return — includes reinvested dividends. ?

Returns over time

YTD+13.8%
1 year+54.3%
3 years+16.9%
5 years+5.6%

How bumpy has it been?

17.7%
Volatility (1y)
How much the price swings year to year — lower is calmer.
-19.6%
Worst drop (3y)
The biggest fall from a peak over the last three years.
0.92
Return for the risk (3y)
Reward earned per unit of bumpiness (the Sharpe ratio) — higher is better.

Price history

9.58 USD latest price · end-of-day · 2026-07-02

4.667.309.94Jul '21Jan '24Jul '26

Weekly closing prices · last 5 years · USD. End-of-day, not live. Past performance doesn’t predict the future.

What your money could grow into

Pick a monthly amount and a number of years to see how regular investing can add up over time. These are your own assumptions — an illustration, not a prediction.

Using iShares Nasdaq US Biotechnology UCITS ETF’s fee. The “assumed yearly return” is just an assumption you can change — not a prediction.

Try:Rough historical ranges — your assumption, not a prediction or advice.
Projected value
You put in
Growth

At year · · you’d have put in , growth added . Drag across the chart (or use ← → keys) to read any year.

Money you added Growth
See the key milestones (every 5 years)
YearPut inGrowthBalance

How this works: an educational scenario, not a forecast. We compound monthly and add your monthly amount each month. “Expected annual return” is your own assumption — pick a cautious one; real markets are bumpy and can fall. “Adjust for inflation” simply restates the result in today’s spending power. The fee figure includes the yearly fund fee (TER) and the growth those fees would otherwise have earned. The fund comparison repeats each fund’s last-12-months return every year — a rough illustration only, which real funds never do. Not advice.

Where it trades

ExchangeTickerCurrency
LSEBTEKUSD★ primary ?
B2BTECUSD
B2BTECEURUSD
B32B70DUSD
B3BTEKLUSD
B3BTECZUSD
B3BTECLUSD
B4BTEKEURUSD
B4BTEKUSDUSD
E1BTEKUSDUSD
E1BTEKEURUSD
E1BTEKGBPUSD
EB2B70DUSD
EBBTECLUSD
EBBTEKLUSD
EPBTEKUSDUSD
EPBTEKEURUSD
EPBTEKGBPUSD
EUBTEKGBPUSD
EUBTEKUSDUSD
EUBTEKEURUSD
EZBTEKEURUSD
EZBTEKGBPUSD
EZBTEKUSDUSD
Frankfurt2B70EUR
GD2B70USD
GF2B70USD
GH2B70USD
GM2B70USD
GS2B70USD
GT2B70USD
GZ2B70USD
I22B70DUSD
IXBTECLUSD
IX2B70DUSD
IXBTEKLUSD
L12B70DUSD
L1BTECLUSD
L1BTECZUSD
L3BTEKLUSD
L3BTECLUSD
L32B70DUSD
L3BTECZUSD
LA2B70USD
London Stock ExchangeBTECUSD
London Stock ExchangeBTEKUSD
LSEBTECUSD
LU2B70USD
MFBTEC1NUSD
MMBTEC1NUSD
MUBTEC1NUSD
POBTEKLUSD
POBTECZUSD
POBTECLUSD
PO2B70DUSD
PQIVBUFUSD
PZBTECUSD
PZBTEKUSD
QE2B70DUSD
QT2B70USD
QXBTECLUSD
QX2B70DUSD
S1BTECLUSD
SEBTECUSD
SIXBTECCHF
T22B70USD
T2BTECUSD
T2BTEKUSD
TH2B70USD
TQBTECLUSD
USIVBUFUSD
UVIVBUFUSD
WT2B70USD
WTBTECUSD
WTBTEKUSD
X2BTEKUSDUSD
X2BTEKGBPUSD
X2BTEKEURUSD
X9BTEKEURUSD
X9BTEKGBPUSD
X9BTEKUSDUSD
XABTEKEURUSD
XABTEKGBPUSD
XABTEKUSDUSD
XBBTEKUSDUSD
XBBTEKGBPUSD
XBBTEKEURUSD
XEBTEKEURUSD
XEBTEKGBPUSD
XEBTEKUSDUSD
XFBTEKUSDUSD
XFBTEKGBPUSD
XFBTEKEURUSD
XGBTEKEURUSD
XGBTEKGBPUSD
XGBTEKUSDUSD
XHBTEKEURUSD
XHBTEKGBPUSD
XHBTEKUSDUSD
XJBTEKUSDUSD
XJBTEKGBPUSD
XJBTEKEURUSD
XLBTEKEURUSD
XLBTEKGBPUSD
XLBTEKUSDUSD
XOBTEKUSDUSD
XOBTEKGBPUSD
XOBTEKEURUSD
XSBTEKEURUSD
XSBTEKGBPUSD
XSBTEKUSDUSD
XUBTEKEURUSD
XUBTEKGBPUSD
XUBTEKUSDUSD
XVBTEKUSDUSD
XVBTEKGBPUSD
XVBTEKEURUSD
XWBTEKEURUSD
XWBTEKGBPUSD
XWBTEKUSDUSD
XXBTEKEURUSD
XXBTEKGBPUSD
XXBTEKUSDUSD

Top holdings ?

Top-holdings (estimate) · as of 2026-07-02
VERTEX PHARMACEUTICALS INC8.4%
AMGEN INC7.9%
GILEAD SCIENCES INC6.9%
REGENERON PHARMACEUTICALS INC4.6%
ALNYLAM PHARMACEUTICALS INC2.8%
REVOLUTION MEDICINES INC2.7%
BIOGEN INC2.2%
MODERNA INC2.1%
ILLUMINA INC1.9%
ARGENX SE ADR1.8%

How concentrated it is ?

The 10 biggest holdings make up 41.3% of this fund.

Where your money goes ?

UNITED STATESUNITED STATES93.1%
BELGIUMBELGIUM1.8%
DENMARKDENMARK1.3%
FRANCEFRANCE1.3%
CHINACHINA0.9%
GERMANYGERMANY0.8%
Other / not shown0.9%

What kinds of companies ?

Health Care100.0%
Other0.2%

Funds a bit like this one

For comparison only — not a suggestion to switch.

Data as of 2026-07-02 · Source: fh-api

New to ETFs? Start with the basics →

Finance Hamster provides educational information about ETFs and investing. It is not investment, tax, or legal advice, and not a recommendation to buy or sell any security. Markets carry risk; do your own research or consult a licensed adviser.